Novartis Ag

Novartis Pharma Gmbh

Neil John Press

Simon James Watson

Urs Baettig

Peter Hunt

Anne-Marie D'Souza

Roger John Taylor

Stephen Paul Collingwood

Clive McCarthy

Brian Cox

Thomas Hugo Keller

Sudhakar Devidasrao Garad

Dimitris Papoutsakis

Hyungchul Kim

Alastair Denholm

Ian Bruce

Robin Alec Fairhurst

David Andrew Sandham

Bernard Cuenoud

David Beattie

Clive Mccarthy

Katharine Louise Turner

Collingwood P Stephen

Reamonn Madden

Anne-Marie D'souza

The present invention relates to compounds of formula (I) wherein X, R, R, R, Rand Rare as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Squaramide derivatives as CXCR2 antagonist

Compounds of formula (I) in salt or zwitterionic form, wherein R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Pyrrolidinium derivatives as M3 muscarnic receptor antagonists

The present invention relates to compounds of formula (I) with the substituents as defined herein, and uses thereof. 

CXC-chemokine receptor ligands

Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Quaternary ammonium salts as M3 antagonists

Compounds of Formula (I); in salt or zwitterionic form wherein R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists

Compounds of formula I in free or salt form, wherein &#x2014;C&#x2014;Y&#x2014;, Rand Rare G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the &#x3b2;-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Quinoline-2-one derivatives for the treatment of airways diseases

Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists

Compounds of formula I in free or salt form, wherein R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-&#x3b1; release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

[1,7]naphthyridines as PDE4 inhibitors

The invention relates to compounds of formula I in free or salt form, where Ris a monovalent aromatic group having up to 10 carbon atoms, and Ris a cycloaliphatic group having up to 8 ring carbon atoms. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.

Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors

Compounds of formula (I) in free or salt form, where A is a C-Cmonovalent aromatic group. Ris hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C&#x2013;C-alkyl, C&#x2013;C-haloalkyl, C&#x2013;C-alkoxy, C&#x2013;C-alkoxy-C&#x2013;C-alkyl or acyloxy, or a 5- or 6-membered monovalent heterocyclic group, Ris hydrogen, C-C-alkyl, acyl or CON(R)R, provided that Ris C&#x2013;C-alkyl, acyl or CON(R)Rwhen Ris hydrogen, Rand Rare each independently hydrogen, or C&#x2013;C-alkyl, together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, and Z, Z, Zand Zare each independently N or CR, at least one of them being CR, and Ris hydrogen, C&#x2013;C-alkyl or C&#x2013;C-alkoxy. The compounds are useful as adenosine receptor antagonists, particularly in the treatment of inflammatory or obstrucive airways diseases 

Aminothaizoles and their use as adenosine receptor antagonists

Growing community of inventors

Horsham, United Kingdom

Neil John Press